Michael G. DeGroote Institute for Infectious Disease Research and the Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Trends Microbiol. 2016 Nov;24(11):862-871. doi: 10.1016/j.tim.2016.06.009. Epub 2016 Jul 15.
Rooted in the mechanism of action of antibiotics and subject to bacterial evolution, antibiotic resistance is difficult and perhaps impossible to overcome. Nevertheless, strategies can be used to minimize the emergence and impact of resistance. Antibiotic adjuvants offer one such approach. These are compounds that have little or no antibiotic activity themselves but act to block resistance or otherwise enhance antibiotic action. Antibiotic adjuvants are therefore delivered in combination with antibiotics and can be divided into two groups: Class I agents that act on the pathogen, and Class II agents that act on the host. Adjuvants offer a means to both suppress the emergence of resistance and rescue the activity of existing drugs, offering an orthogonal strategy complimentary to new antibiotic discovery VIDEO ABSTRACT.
抗生素耐药性根植于抗生素的作用机制,且易受细菌进化的影响,因此难以甚至不可能克服。然而,可以采用一些策略来最大程度地减少耐药性的出现和影响。抗生素增效剂就是一种方法。这些化合物本身几乎没有或没有抗生素活性,但可起到阻止耐药性或增强抗生素作用的作用。因此,抗生素增效剂与抗生素联合使用,并可分为两类:作用于病原体的 I 类药物和作用于宿主的 II 类药物。增效剂提供了一种既可以抑制耐药性出现又可以恢复现有药物活性的手段,是一种与新型抗生素发现相辅相成的正交策略。